SCHEMBL5203225

SCHEMBL5203225

COc1cc(-c2ccc(N(C)CCN(C)c3ccc(-c4cc(OC)c(C(=O)N(C)OC)c(OC)c4)nc3)cn2)cc(OC)c1C(=O)N(C)OC

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36
GPR119 Q8TDV5 6/20 0.33
SYK P43405 1/20 0.33
FYN P06241 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33
OXTR P30559 1/20 0.33
FGFR1 P11362 2/20 0.33
FFAR4 Q5NUL3 1/20 0.32
PDE4B Q07343 1/20 0.32
LPAR5 Q9H1C0 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
GRK5 P34947 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR4 P22455 1/20 0.32
FGFR3 P22607 1/20 0.32
KDR P35968 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5207435 0.87 FYN (0.36) SYKFYNFGFR1FFAR4MEN1
SCHEMBL5208926 0.82 FLT1 (0.35) SYKFYNFGFR1GRK5KDR
SCHEMBL5205270 0.82 SUV39H2 (0.35) GPR119SYKFYNFGFR1FFAR4
SCHEMBL5207615 0.81 SMPD3 (0.41) MTORFYN
SCHEMBL5208377 0.81 HPGD (0.34) SYKFYNFGFR1GRK5
Trifluoroacetic Acid SCHEMBL5208472 0.81 CA12 (0.37) FYNGPBAR1FGFR1FFAR4PDE4B
SCHEMBL5210909 0.80 KDM1A (0.37) FYNFGFR1FGFR2FGFR4FGFR3
SCHEMBL5207852 0.80 FYN (0.43) FYN
SCHEMBL5204509 0.79 KDM1A (0.46) FYNFGFR1FFAR4FGFR2FGFR4
SCHEMBL5208946 0.79 PDGFRB (0.37) FYNFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1403251-B1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE KOWA CO (JP) 2007-07-18 EP disclosed
US-6890940-B2 Bis(2-aryl-5-pyridyl) derivatives KOWA CO., LTD. (JP) 2005-05-10 US disclosed
EP-1403251-A1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE Kowa Co., Ltd. (JP) 2004-03-31 EP disclosed
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022886-A1 Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy IGLV6-57, IL5, IGSF11 PIK3CA 2527/4885MTOR 1890/4885GPR119 1529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.